United States Biotechnology & Medical Research

Zymeworks Inc (ZYME)

Track

Zymeworks Inc. has seen no insider trading activity in the last three months. The most recent transactions occurred between January and March 2026, consisting primarily of proposed sales and direct sales by various officers and directors, including the CEO and former officers. These activities concluded on March 6, 2026.
Ticker: ZYME Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Zymeworks Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 6 Mar 2026
Value US$3,409,629.26 | Price 491.89 | Shares 77,907
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-06 2026-03-06 PrS Proposed sale
2.5
Jeffrey T L Smith

Former Officer

Officer
77,907
491.89
US$3,409,629 		77,907 491.89 US$3,409,629
2026-02-17 2026-02-17 PrS Proposed sale
3.8
Leone D Patterson

Former officer

Officer
26,121
335.30
US$3,111,964 		26,121 335.30 US$3,111,964
2026-02-13 2026-02-13 PrS Proposed sale
3.8
Leone D Patterson

Former officer

Officer
42,861
98.52
US$2,777,784 		42,861 98.52 US$2,777,784
2026-01-13 2026-01-12 S Sale
0.9
Hollywood Mark

EVP & Chief Operating Officer

Officer
6,120 -4.4%
22.67
US$138,762 		6,120 -4.4% 22.67 US$138,762
2026-01-12 2026-01-12 PrS Proposed sale
3.8
Leone D Patterson

Former officer

Officer
6,832
23.17
US$158,297 		6,832 23.17 US$158,297
2026-01-12 2026-01-12 PrS Proposed sale
2.5
Jeffrey T L Smith

Officer

Officer
9,310
23.17
US$215,713 		9,310 23.17 US$215,713
2026-01-12 2026-01-12 PrS Proposed sale
2.9
Paul Andrew Moore

Officer

Officer
9,560
23.17
US$221,505 		9,560 23.17 US$221,505
2026-01-12 2026-01-12 PrS Proposed sale
0.9
Mark Hollywood

Officer

Officer
6,120
23.17
US$141,800 		6,120 23.17 US$141,800
2026-01-12 2026-01-12 PrS Proposed sale
3.2
Kenneth Galbraith

Officer; Director

Executive Director
30,424
23.17
US$704,924 		30,424 23.17 US$704,924
2026-01-12 2026-01-12 S Sale
2.5
Smith Jeffrey T L

EVP & Chief Medical Officer

Officer
9,310 -25.8%
22.67
US$211,090 		9,310 -25.8% 22.67 US$211,090
2026-01-12 2026-01-12 S Sale
2.9
Moore Paul Andrew

Chief Scientific Officer

Officer
9,560 -16.5%
22.67
US$216,759 		9,560 -16.5% 22.67 US$216,759
2026-01-12 2026-01-12 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
30,424 -11.8%
22.67
US$689,819 		30,424 -11.8% 22.67 US$689,819
2026-01-05 2026-01-05 PrS Proposed sale
2.5
Smith Jeffrey T L

Officer

Officer
10,538
26.62
US$280,522 		10,538 26.62 US$280,522
2026-01-05 2026-01-05 PrS Proposed sale
3.2
Kenneth Galbraith

Officer; Director

Executive Director
54,343
26.62
US$1,446,611 		54,343 26.62 US$1,446,611
2026-01-05 2026-01-05 PrS Proposed sale
2.9
Paul Andrew Moore

Officer

Officer
20,110
26.62
US$535,328 		20,110 26.62 US$535,328
2026-01-05 2026-01-05 S Sale
2.5
Smith Jeffrey T L

EVP & Chief Medical Officer

Officer
10,538 -36.5%
25.10
US$264,471 		10,538 -36.5% 25.10 US$264,471
2026-01-05 2026-01-05 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
31,686 -14.1%
25.10
US$795,220 		31,686 -14.1% 25.10 US$795,220
2026-01-05 2026-01-05 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
22,657 -12.5%
25.10
US$568,620 		22,657 -12.5% 25.10 US$568,620
2026-01-05 2026-01-05 S Sale
2.9
Moore Paul Andrew

Chief Scientific Officer

Officer
10,821 -21.1%
25.10
US$271,574 		10,821 -21.1% 25.10 US$271,574
2026-01-05 2026-01-05 S Sale
2.9
Moore Paul Andrew

Chief Scientific Officer

Officer
9,289 -22.9%
25.10
US$233,125 		9,289 -22.9% 25.10 US$233,125
2025-12-22 2025-12-22 PrS Proposed sale
3.2
Galbraith, Kenneth

Officer; Director

Executive Director
47,528
27.23
US$1,294,187 		47,528 27.23 US$1,294,187
2025-12-22 2025-12-22 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
47,528 -26.3%
27.02
US$1,284,311 		47,528 -26.3% 27.02 US$1,284,311
2025-11-24 2025-11-24 PrS Proposed sale
Derek John Michael Miller

Former Director

Non-Executive Director
118,000
23.82
US$2,810,760 		118,000 23.82 US$2,810,760
2025-11-21 2025-11-21 PrS Proposed sale
3.2
Neil Gallagher

Former Director

Non-Executive Director
105,000
23.82
US$2,501,100 		105,000 23.82 US$2,501,100
2025-05-19 2025-05-19 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
5,919 +0.0%
11.78
US$69,738 		5,919 +0.0% 11.78 US$69,738
2025-05-19 2025-05-15 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
49,502 +0.3%
11.43
US$565,847 		49,502 +0.3% 11.43 US$565,847
2025-04-18 2025-04-17 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
54,760 +0.3%
11.52
US$630,819 		54,760 +0.3% 11.52 US$630,819
2025-04-18 2025-04-16 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
73,953 +0.4%
11.16
US$825,589 		73,953 +0.4% 11.16 US$825,589
2025-04-07 2025-04-04 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
196,438 +1.1%
11.17
US$2,193,800 		196,438 +1.1% 11.17 US$2,193,800
2025-04-07 2025-04-03 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
120,770 +0.7%
11.84
US$1,430,170 		120,770 +0.7% 11.84 US$1,430,170
2025-04-02 2025-04-02 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
74,360 +0.4%
11.85
US$881,017 		74,360 +0.4% 11.85 US$881,017
2025-04-02 2025-04-01 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
48,658 +0.3%
11.60
US$564,647 		48,658 +0.3% 11.60 US$564,647
2025-04-02 2025-03-31 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
4,397 +0.0%
11.75
US$51,658 		4,397 +0.0% 11.75 US$51,658
2025-03-27 2025-03-26 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
43,848 +0.3%
12.24
US$536,857 		43,848 +0.3% 12.24 US$536,857
2025-03-27 2025-03-25 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
53,501 +0.3%
12.91
US$690,452 		53,501 +0.3% 12.91 US$690,452
2025-03-24 2025-03-24 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
22,689 +0.1%
13.08
US$296,847 		22,689 +0.1% 13.08 US$296,847
2025-03-24 2025-03-21 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
31,033 +0.2%
12.78
US$396,518 		31,033 +0.2% 12.78 US$396,518
2025-03-24 2025-03-20 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
73,476 +0.4%
12.93
US$949,883 		73,476 +0.4% 12.93 US$949,883
2025-03-19 2025-03-19 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
58,306 +0.3%
12.64
US$737,233 		58,306 +0.3% 12.64 US$737,233
2025-03-19 2025-03-18 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
113,880 +0.7%
12.65
US$1,440,855 		113,880 +0.7% 12.65 US$1,440,855
2025-03-19 2025-03-17 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
56,277 +0.3%
12.23
US$688,465 		56,277 +0.3% 12.23 US$688,465
2025-03-13 2025-03-13 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
468,356 +2.9%
12.48
US$5,847,237 		468,356 +2.9% 12.48 US$5,847,237
2025-03-13 2025-03-12 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
292,934 +1.8%
12.25
US$3,587,826 		292,934 +1.8% 12.25 US$3,587,826
2025-03-13 2025-03-11 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
320,690 +2.0%
11.49
US$3,685,851 		320,690 +2.0% 11.49 US$3,685,851
2025-01-21 2025-01-17 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
19,748 +0.1%
13.87
US$273,998 		19,748 +0.1% 13.87 US$273,998
2025-01-21 2025-01-16 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
121,681 +0.8%
13.89
US$1,689,541 		121,681 +0.8% 13.89 US$1,689,541
2025-01-15 2025-01-15 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
39,029 +0.3%
14.01
US$546,671 		39,029 +0.3% 14.01 US$546,671
2025-01-15 2025-01-14 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
54,500 +0.4%
13.56
US$739,265 		54,500 +0.4% 13.56 US$739,265
2025-01-15 2025-01-13 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
74,125 +0.5%
13.39
US$992,875 		74,125 +0.5% 13.39 US$992,875
2025-01-10 2025-01-10 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
204,098 +1.3%
13.13
US$2,678,990 		204,098 +1.3% 13.13 US$2,678,990
2025-01-10 2025-01-08 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
21,021 +0.1%
14.07
US$295,829 		21,021 +0.1% 14.07 US$295,829
2025-01-06 2025-01-06 PrS Proposed sale
2.5
Smith Jeffrey T L

Officer

Officer
11,110
14.46
US$160,651 		11,110 14.46 US$160,651
2025-01-06 2025-01-06 PrS Proposed sale
2.9
Moore Paul Andrew

Officer

Officer
21,200
14.46
US$306,552 		21,200 14.46 US$306,552
2025-01-06 2025-01-06 PrS Proposed sale
3.2
Galbraith, Kenneth

Officer; Director

Executive Director
57,291
14.46
US$828,428 		57,291 14.46 US$828,428
2025-01-06 2025-01-06 S Sale
2.9
Moore Paul Andrew

Chief Scientific Officer

Officer
11,408 -32.8%
14.92
US$170,254 		11,408 -32.8% 14.92 US$170,254
2025-01-06 2025-01-06 S Sale
2.9
Moore Paul Andrew

Chief Scientific Officer

Officer
9,792 -39.9%
14.92
US$146,137 		9,792 -39.9% 14.92 US$146,137
2025-01-06 2025-01-06 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
33,406 -29.2%
14.92
US$498,554 		33,406 -29.2% 14.92 US$498,554
2025-01-06 2025-01-06 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
23,885 -33.4%
14.92
US$356,462 		23,885 -33.4% 14.92 US$356,462
2025-01-06 2025-01-06 S Sale
2.5
Smith Jeffrey T L

EVP & Chief Medical Officer

Officer
11,110 -55.5%
14.92
US$165,807 		11,110 -55.5% 14.92 US$165,807
2025-01-02 2025-01-02 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
157,880 +1.1%
14.78
US$2,333,403 		157,880 +1.1% 14.78 US$2,333,403
2025-01-02 2024-12-31 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
146,501 +1.0%
14.57
US$2,134,446 		146,501 +1.0% 14.57 US$2,134,446
2025-01-02 2024-12-30 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
58,988 +0.4%
14.47
US$853,326 		58,988 +0.4% 14.47 US$853,326
2024-12-27 2024-12-27 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
101,659 +0.7%
14.49
US$1,473,181 		101,659 +0.7% 14.49 US$1,473,181
2024-12-27 2024-12-26 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
16,692 +0.1%
14.38
US$240,038 		16,692 +0.1% 14.38 US$240,038
2024-12-27 2024-12-24 B Purchase
3.1
EcoR1 Capital, LLC
Non-Executive Director Large shareholder
11,958 +0.1%
14.12
US$168,896 		11,958 +0.1% 14.12 US$168,896
2024-06-11 2024-06-11 PrS Proposed sale
2.4
Christopher Astle

Former Officer

Officer
86,294
8.97
US$774,057 		86,294 8.97 US$774,057
2024-01-08 2024-01-08 S Sale
2.4
Astle Christopher

SVP & Chief Financial Officer

Officer
1,431 -18.0%
11.22
US$16,050 		1,431 -18.0% 11.22 US$16,050
2024-01-08 2024-01-08 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
5,706 -19.4%
11.22
US$63,996 		5,706 -19.4% 11.22 US$63,996
2024-01-08 2024-01-08 S Sale
2.9
Moore Paul Andrew

Chief Scientific Officer

Officer
2,339 -24.1%
11.22
US$26,233 		2,339 -24.1% 11.22 US$26,233
2024-01-08 2024-01-05 S Sale
2.4
Astle Christopher

SVP & Chief Financial Officer

Officer
4,563 -36.5%
10.65
US$48,606 		4,563 -36.5% 10.65 US$48,606
2024-01-08 2024-01-05 S Sale
3.2
Galbraith Kenneth

Chair & CEO

Executive Director
18,198 -38.2%
10.65
US$193,849 		18,198 -38.2% 10.65 US$193,849
2024-01-08 2024-01-05 S Sale
2.9
Moore Paul Andrew

Chief Scientific Officer

Officer
7,460 -43.5%
10.65
US$79,465 		7,460 -43.5% 10.65 US$79,465
2024-01-05 2024-01-05 PrS Proposed sale
2.4
Astle Christopher

Officer

Officer
5,994
10.56
US$63,297 		5,994 10.56 US$63,297
2024-01-05 2024-01-05 PrS Proposed sale
3.2
Galbraith, Kenneth

Officer; Director

Executive Director
23,904
10.56
US$252,427 		23,904 10.56 US$252,427
2024-01-05 2024-01-05 PrS Proposed sale
2.9
Moore Paul Andrew

Officer

Officer
9,799
10.56
US$103,478 		9,799 10.56 US$103,478
Explore more

More insider trading research around Zymeworks Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America